Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus DARVOCET N 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus DARVOCET N 50.
ASTRAMORPH PF vs DARVOCET-N 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Propoxyphene is a weak mu-opioid receptor agonist; it also binds to sigma receptors. Acetaminophen inhibits prostaglandin synthesis via COX-1 and COX-2, thereby reducing pain and fever.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
1 tablet (propoxyphene 50 mg, acetaminophen 300 mg) orally every 4 hours as needed for pain, not to exceed 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Acetaminophen: 1.5-3 hours (therapeutic); 4-6 hours in overdose due to saturation of metabolism. Propoxyphene: 6-12 hours (parent); norpropoxyphene: 30-36 hours (active metabolite, accumulates with repeated dosing).
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Acetaminophen: renal (90-100% as metabolites within 24h; 2-4% unchanged). Propoxyphene: renal (25-30% unchanged; metabolites) and biliary/fecal (significant enterohepatic circulation).
Category C
Category C
Opioid Analgesic
Opioid Analgesic